According to a recent cohort study, patients with inflammatory rheumatic and musculoskeletal diseases receiving rituximab therapy experience more severe COVID-19. Researchers also found an association between rituximab use and prolonged hospital stays.
![](https://www.the-rheumatologist.org/wp-content/uploads/2020/03/GettyImages_Coronavirus_500x250-150x150.jpg)